Journal article
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
Abstract
BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment-resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine …
Authors
Jesus‐Nunes AP; Leal GC; Correia‐Melo FS; Vieira F; Mello RP; Caliman‐Fontes AT; Echegaray MVF; Marback RF; Guerreiro‐Costa LNF; Souza‐Marques B
Journal
Human Psychopharmacology Clinical and Experimental, Vol. 37, No. 4,
Publisher
Wiley
Publication Date
July 2022
DOI
10.1002/hup.2836
ISSN
0885-6222